vPrint Library: ROCKET AF Results

Presented by Bruce Stambler, MD An overview of the ROCKET AF trial, which compared once-daily XARELTO® to dose-adjusted warfarin in patients with nonvalvular atrial fibrillation. This multinational trial involved more than 14,000 patients with atrial fibrillation (AF) and moderate-to-high stroke risk (mean...

Presented by Bruce Stambler, MD The large, multinational ROCKET AF trial found the select Factor Xa inhibitor, XARELTO®, to be noninferior to warfarin in preventing stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. Previous videos in...

Presented by Bruce Stambler, MD The multinational ROCKET AF trial compared XARELTO® to warfarin in more than 14,000 patients with nonvalvular atrial fibrillation and moderate-to-high stroke risk. It established that XARELTO® is noninferior to warfarin for reducing the risk of stroke and embolism in...